Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Randomization	STARTED	Nivolumab + Radiation Therapy	280
Randomization	STARTED	Temozolomide + Radiation Therapy	280
Randomization	COMPLETED	Nivolumab + Radiation Therapy	278
Randomization	COMPLETED	Temozolomide + Radiation Therapy	275
Randomization	NOT COMPLETED	Nivolumab + Radiation Therapy	2
Randomization	NOT COMPLETED	Temozolomide + Radiation Therapy	5
Treatment	STARTED	Nivolumab + Radiation Therapy	278
Treatment	STARTED	Temozolomide + Radiation Therapy	275
Treatment	COMPLETED	Nivolumab + Radiation Therapy	0
Treatment	COMPLETED	Temozolomide + Radiation Therapy	76
Treatment	NOT COMPLETED	Nivolumab + Radiation Therapy	278
Treatment	NOT COMPLETED	Temozolomide + Radiation Therapy	199

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02617589/flow